Author's Reply: “Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?”
We have read with interest the comments on our article [1] by Yuksel et al. [2] and we thank them for their valuable insight. The authors highlighted the main conclusion of our study: there were no differences between the combination treatment group (thiopurines with infliximab) and infliximab monotherapy group regarding the occurrence of a composite outcome used to d efine disease progression.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Paula Sousa, Fernando Magro Tags: Correspondence Source Type: research